Logo of Eleva

Eleva

Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biologics based on a breakthrough moss-based technology platform. The company’s proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. Dry AMD has been selected as the second indication. The company’s aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programs are sourced from Eleva’s transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with tremendous therapeutic potential.

Content by Eleva

Close-Up Shot of an Elderly Senior Caucasian Woman's Eyes and Face
| 2 min read
Industry Perspectives
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Mapping cancer signaling at single cell resolution
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Application Note
10x Genomics Logo
Illustration of an antibody intertwined with a DNA double helix.
Mapping immune disease variants at genome scale
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Webinars
BD Bio
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
From absorption to metabolism: predicting human oral drug exposure
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.
Webinars
CN Bio Logo